Johanna Jost

Ms. Johanna Jost

Department of Neurosurgery, Münster University Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
FTFabian M. Troschel
Fabian M. Troschel
FAFranziska Ahndorf
Franziska Ahndorf
LWLisa-Marie Wille
Lisa-Marie Wille
RBRalf Brandt
Ralf Brandt
JJJohanna Jost
Johanna Jost
DWDorothee Wiewrodt
Dorothee Wiewrodt
The COVID-19 pandemic is associated with significant morbidity, mortality, and restrictions on everyday life worldwide. This may be especially challenging for brain tumor patients given increased vulnerability due to their pre-existing condition. Here, we aimed to investigate the quality of life (QoL) in brain tumor patients and relatives in this setting. Over twelve weeks during the first wave of the pandemic (04–07/2020), brain tumor patients and their families from two large German tertiary care centers were asked to complete weekly questionnaires for anxiety, depression, distress, and well-being. Information regarding social support and living conditions was also collected. One hundred participants (63 patients, 37 relatives) completed 729 questionnaires over the course of the study. Compared to relatives, patients showed more depressive symptoms (p < 0.001) and reduced well-being (p = 0.013). While acceptance of lockdown measures decreased over time, QoL remained stable. QoL measures between patients and their families were weakly or moderately correlated. The number of social contacts was strongly associated with QoL. Age, living conditions, ongoing therapy, employment, and physical activity were other predictors. QoL is correlated between patients and their families and heavily depends on social support factors, indicating the need to focus on the entire family and their social situation for QoL interventions during the pandemic.

12 June 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JJJohanna Jost
Johanna Jost
MMMichael Müther
Michael Müther
RBRalf Brandt
Ralf Brandt
UAUgur Altuner
Ugur Altuner
LLLars Lemcke
Lars Lemcke
DWDorothee Wiewrodt
Dorothee Wiewrodt
Purpose: Exercise proved to reduce cancer-related symptoms and prolong survival in some cancer types. However, brain tumor patients are often advised against strenuous exercise. Here, we summarize our experience with a submaximal exercise program for glioma patients: ActiNO (Active in Neuro-Oncology). Methods: Glioma patients were invited to participate in the program. Since 2011, a sports scientist individualized two one-hour sessions per week adapted to the patients’ symptoms. One session consisted of bicycle ergometry (average workload: 75% of maximum heart rate), the other of whole-body resistance training. Both sessions were further complimented by coordinative elements. Cardiorespiratory fitness was assessed using the ”Physical Work Capacity” procedure. Patients were followed up regularly to assess adherence to the program and disease activity. Results: Until December 2019, 45 glioma patients, median-aged 49 years (IQR 42–59), were included in the analysis. Most patients suffered from glioblastoma (58%), followed by diffuse lower-grade astrocytoma (29%). In overall 1828 training sessions, two minor epileptic events occurred (1 speech arrest; 1 focal seizure). During fitness assessment, all patients achieved at least 75% of their age-adjusted maximum heart rate. Peak workload averaged 172 W (95% CI 156–187). Median survival of participating glioblastoma patients was 24.1 months (95% CI 8.6–39.5). Conclusion: This supervised training program with submaximal exertion was feasible and safe in glioma regardless of WHO grading. Based on these experiences, we initiated a prospective multicenter study to objectify improvements in physical performance and quality of life in patients with glioblastoma.

28 March 2024 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
FTFabian M. Troschel
Fabian M. Troschel
BTBenjamin O. Troschel
Benjamin O. Troschel
MKMaren Kloss
Maren Kloss
JJJohanna Jost
Johanna Jost
NPNiklas Benedikt Pepper
Niklas Benedikt Pepper
HEHans Theodor Eich
Hans Theodor Eich
Purpose: Sarcopenia may complicate treatment in cancer patients. Herein, we assessed whether sarcopenia measurements derived from radiation planning computed tomography (CT) were associated with complications and tumor progression during radiochemotherapy for glioblastoma. Methods: Consecutive patients undergoing radiotherapy planning for glioblastoma between 2010 and 2021 were analyzed. Retrocervical muscle cross-sectional area (CSA) was measured via threshold-based semi-automated radiation planning CT analysis. Patients in the lowest sex-specific quartile of muscle measurements were defined as sarcopenic. We abstracted treatment characteristics and tumor progression from the medical records and performed uni- and multivariable time-to-event analyses. Results: We included 363 patients in our cohort (41.6% female, median age 63 years, median time to progression 7.7 months). Sarcopenic patients were less likely to receive chemotherapy (p < 0.001) and more likely to be treated with hypofractionated radiotherapy (p = 0.005). Despite abbreviated treatment, they more often discontinued radiotherapy (p = 0.023) and were more frequently prescribed corticosteroids (p = 0.014). After treatment, they were more often transferred to inpatient palliative care treatment (p = 0.035). Finally, progression-free survival was substantially shorter in sarcopenic patients in univariable (median 5.1 vs. 8.4 months, p < 0.001) and multivariable modeling (hazard ratio 0.61 [confidence interval 0.46–0.81], p = 0.001). Conclusion: Sarcopenia is a strong risk factor for treatment discontinuation and reduced progression-free survival in glioblastoma patients. We propose that sarcopenic patients should receive intensified supportive care during radiotherapy and during follow-up as well as expedited access to palliative care.

25 July 2025 in Neuro-Oncology
Verified
Journal Article
Open access
JJJohanna Jost
Johanna Jost
RKRalf Ketter
Ralf Ketter
RBRalf Brandt
Ralf Brandt
KVKlaus Völker
Klaus Völker
JGJoachim Gerß
Joachim Gerß
DWDorothee Wiewrodt
Dorothee Wiewrodt
Background: High-grade glioma (HGG) patients experience enormous disease burden both from tumor- and treatment-related symptoms. Exercise can improve physical fitness and quality of life (QoL); yet experience in neuro-oncology, especially with high-intensity exercise, remains limited. This study evaluated feasibility, safety, and efficacy of the intensive, structured 16-week strength and endurance program, “Active in Neuro-Oncology” (ActiNO) for HGG patients undergoing chemotherapy. Methods: In this prospective, oligocentric, single-arm proof-of-concept trial, 54 HGG patients participated in ActiNO, with twice-weekly supervised exercise sessions. The primary endpoint was cardiorespiratory fitness, assessed via physical working capacity (PWC75%)—the workload (W/kg body weight) achieved at 75% of age-adjusted maximum heart rate during a maximal cardiopulmonary exercise test. Secondary endpoints included peak oxygen uptake (VO2peak), peak power output (Ppeak), and QoL (EORTC QLQ-C30). Analyses focused on within-subject changes from pre- to post-intervention. Additionally, comparisons to normative data were performed. Feasibility was assessed via accrual, adherence, and attrition; safety via adverse event monitoring (CTCAE). Results: Program tolerance was high, with few exercise-related adverse events (all CTCAE grade 1-2). Over 16 weeks, significant improvements were observed in PWC75% (1.023-1.256 W/kg BW, +23%), VO2peak (23.04-26.09 ml/min/kg BW, +13%), and Ppeak (1.771-2.104 W/kg BW, +19%). QoL, including global health and physical functioning, improved, reaching normative values. Adherence was high (85%), though attrition was 48%, mainly due to disease progression or physical constraints. Conclusions: High-intensity exercise is feasible and safe in HGG patients undergoing chemotherapy. The observed improvements in physical fitness and QoL support incorporating structured exercise into neuro-oncology care.

1 April 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JJJohanna Jost
Johanna Jost
KVKlaus Völker
Klaus Völker
RBRalf Brandt
Ralf Brandt
WSWalter Stummer
Walter Stummer
SUSteffi Urbschat
Steffi Urbschat
FBFreerk Baumann
Freerk Baumann
Purpose: Maximal cardiopulmonary exercise testing (max. CPET) provides the most accurate measurement of cardiorespiratory fitness. However, glioblastoma (GBM) patients often undergo less intensive tests, e.g., 6-min walk test or self-rating scales. This study aims to demonstrate feasibility and safety of max. CPET in GBM patients, concurrently evaluating their physical fitness status. Methods: Newly diagnosed GBM patients undergoing adjuvant chemotherapy were offered participation in an exercise program. At baseline, max. CPET assessed cardiorespiratory fitness including peak oxygen consumption (VO2peak), peak workload, and physical work capacity (PWC) at 75% of age-adjusted maximal heart rate (HR). Criteria for peak workload were predefined based on threshold values in HR, respiratory quotient, respiratory equivalent, lactate, and rate of perceived effort. Data were compared to normative values. Adverse events were categorized according to standardized international criteria. Further, self-reported exercise data pre- and post-diagnosis were gathered. Results: All 36 patients (median-aged 60; 21 men) met the predefined criteria for peak workload. Mean absolute VO2peak was 1750 ± 529 ml/min, peak workload averaged 130 ± 43 W, and mean PWC was 0.99 ± 0.38 W/kg BW, all clinically meaningful lower than age- and sex-predicted normative values (87%, 79%, 90%, resp.). Only once (3%) a minor, transient side effect occurred (post-test dizziness, no intervention needed). Self-reported exercise decreased from 15.8 MET-h/week pre-diagnosis to 7.2 MET-h/week post-diagnosis. Conclusion: Max. CPET in this well-defined population proved feasible and safe. GBM patients exhibit reduced cardiorespiratory fitness, indicating the need for tailored exercise to enhance health and quality of life. CPET could be essential in establishing precise exercise guidelines.

24 April 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
JJJohanna Jost
Johanna Jost
KVKlaus Völker
Klaus Völker
RBRalf Brandt
Ralf Brandt
WSWalter Stummer
Walter Stummer
SUSteffi Urbschat
Steffi Urbschat
FBFreerk Baumann
Freerk Baumann